<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
    xmlns:content="http://purl.org/rss/1.0/modules/content/"
    xmlns:media="http://search.yahoo.com/mrss/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title><![CDATA[Pharma – AI Global News]]></title>
        <link>https://www.healthbiz.in/rss/category/pharma</link>
        <atom:link href="https://www.healthbiz.in/rss/category/pharma" rel="self" type="application/rss+xml" />
        <description><![CDATA[Latest Pharma news from AI Global News. ]]></description>
        <language>en-us</language>
        <pubDate>Tue, 17 Nov 2026 13:24:47 +0000</pubDate>
        <lastBuildDate>Tue, 17 Nov 2026 13:24:47 +0000</lastBuildDate>
        <managingEditor>editor@aiglobalnews.com (AI Global News)</managingEditor>
        <webMaster>webmaster@aiglobalnews.com</webMaster>
        <category><![CDATA[Pharma]]></category>
        <ttl>60</ttl>

        
                    <item>
                <title><![CDATA[Lupin Appoints Akhil Gupta as Independent Director for Five-Year Term]]></title>
                <link>https://www.healthbiz.in/lupin-appoints-akhil-gupta-as-independent-director-for-five-year-term</link>
                <guid isPermaLink="true">https://www.healthbiz.in/lupin-appoints-akhil-gupta-as-independent-director-for-five-year-term</guid>
                <description><![CDATA[]]></description>
                <content:encoded><![CDATA[<p><strong>Mumbai-based pharmaceutical major Lupin Limited has appointed business leader and Chartered Accountant Akhil Gupta as an Additional Director (Non-Executive, Independent), strengthening its board with more than four decades of experience in corporate strategy, finance, governance and business development.</strong></p>
<p>Lupin Limited has announced the appointment of Akhil Gupta as an Additional Director (Non-Executive, Independent) to its Board, effective November 3, 2026.</p>
<p>The appointment was unanimously approved by the company's Board of Directors following a recommendation from the Nomination and Remuneration Committee. Gupta will serve a five-year term as an Independent Director, from November 3, 2026, to November 2, 2031, subject to approval by the company's members.</p>
<h2>Extensive Experience in Corporate Leadership</h2>
<p>A qualified Chartered Accountant, Akhil Gupta brings over 40 years of professional experience spanning corporate strategy, business development, financial management, mergers and acquisitions, and corporate governance. He has also completed the Advanced Management Program at Harvard Business School, Harvard University.</p>
<p>During his career, Gupta served as Vice Chairman of Bharti Enterprises Limited, where he played a significant role in the group's expansion through organic growth and strategic acquisitions.</p>
<p>He currently holds several prominent corporate positions, including Non-Executive Independent Chairman of 360 ONE WAM Limited, Coforge Limited and Valuedrive Technologies Limited (Spinny). He also serves as an Independent Director at Lodha Developers Limited and Zepto Limited, and as a Nominee Director of Acevector Limited.</p>
<h2>Contributions Across Industry and Policy</h2>
<p>Beyond his corporate board responsibilities, Gupta is the President of the Telecom Sector Skill Council and Chairman of Inversion Advisory Services.</p>
<p>He has also been associated with the Confederation of Indian Industry (CII), including its National Committee on Telecom and Broadband and Task Force on Insolvency and Bankruptcy.</p>
<p>His previous industry and policy engagements include leadership at the Digital Infrastructure Providers Association and participation in advisory committees associated with the Insolvency and Bankruptcy Board of India and the Government of India's Insolvency Law Committee.</p>
<p>Through Inversion Advisory Services, he advises businesses across sectors such as infrastructure, renewable energy, automobiles, tourism and other industries.</p>
<h2>Recognitions and Industry Achievements</h2>
<p>Gupta has received several professional distinctions during his career, including the EY Entrepreneur of the Year Award in the Entrepreneur CEO category, CA Global Achiever Award, CA Business Achiever Award and CEO of the Year Award.</p>
<p>His other recognitions include Lifetime Achievement Awards from ET Telecom, Voice &amp; Data, the Institute of Chartered Accountants of India (ICAI) and Amity University, along with multiple CNBC-TV18 Best CFO Awards. He has also been inducted into the CFO India Hall of Fame.</p>
<h2>Lupin's Board Strengthening Strategy</h2>
<p>Commenting on the appointment, Manju D. Gupta, Chairperson of Lupin, welcomed Akhil Gupta to the Board and highlighted his strategic perspective, financial expertise, governance experience and track record of building large businesses.</p>
<p>The company stated that his experience would contribute to Lupin's efforts to strengthen its global position and pursue its next phase of growth.</p>
<p>Headquartered in Mumbai, Lupin Limited operates across India, the United States, other developed markets and emerging markets, with its products available in more than 100 markets.</p>
<p>Its portfolio includes generics, complex generics, specialty medicines and biosimilars. The company has significant operations across cardiovascular, respiratory, diabetes, gastrointestinal and women's health segments.</p>
<p>Lupin operates 15 manufacturing facilities and six research centres, supported by a workforce of more than 26,000 employees. Its broader healthcare operations also include diagnostics, digital health, patient-support programmes and disease management initiatives.</p>
<p>The appointment comes as Lupin continues to strengthen its corporate governance and board-level leadership to support its global pharmaceutical business.</p>]]></content:encoded>
                <dc:creator><![CDATA[AI Global]]></dc:creator>
                <pubDate>Thu, 05 Nov 2026 11:53:26 +0000</pubDate>

                                    <media:content url="/storage/media/images/1793879581_6abb81c391c40-coforge-appoints-akhil-gupta-as-chairman-291536898-16x9_article.webp" medium="image">
                        <media:title type="html"><![CDATA[Lupin Appoints Akhil Gupta as Independent Director for Five-Year Term]]></media:title>
                    </media:content>
                    <enclosure url="/storage/media/images/1793879581_6abb81c391c40-coforge-appoints-akhil-gupta-as-chairman-291536898-16x9_article.webp" length="0" type="image/jpeg" />
                
                                    <category><![CDATA[Pharma]]></category>
                            </item>
                    <item>
                <title><![CDATA[Celevida GLP+ FSSAI Alert Keeps Sales Running]]></title>
                <link>https://www.healthbiz.in/celevida-glp-fssai-alert-keeps-sales-running-6adba4ea2d461</link>
                <guid isPermaLink="true">https://www.healthbiz.in/celevida-glp-fssai-alert-keeps-sales-running-6adba4ea2d461</guid>
                <description><![CDATA[Dr Reddy&#039;s can keep selling Celevida GLP+ for now. What it may not be able to keep doing is calling it whatever it likes. The company has confirmed it is review...]]></description>
                <content:encoded><![CDATA[<p>Dr Reddy's can keep selling Celevida GLP+ for now. What it may not be able to keep doing is calling it whatever it likes. The company has confirmed it is reviewing both the product's brand name and the claims used to advertise it, after a notice from the Food Safety and Standards Authority of India.</p>
<p>The detail that matters most to shoppers: nothing has been pulled off the shelf. According to the company's own account of the communication, FSSAI asked Dr Reddy's to continue selling the product while the regulator examines the claims it flagged.</p>
<h2>Keep Selling, Keep Explaining: The Unusual Shape of This Notice</h2>
<p>Most food-safety actions in India end with a recall, a seizure or a public clarification. This one has not. The regulator's instruction, as described by the company, is essentially: carry on with sales, but answer for the claims.</p>
<p>That makes it a scrutiny of language rather than of safety. It also puts the spotlight on a single question &mdash; how much medical-sounding vocabulary a nutrition product can carry before a regulator decides it has crossed from marketing into a health promise.</p>
<h2>Why the Words "GLP+" Sit in a Regulatory Grey Zone</h2>
<p>GLP-1 refers to a class of medicines &mdash; the injectable and oral drugs that have reshaped global weight-loss treatment. A nutrition brand that borrows "GLP+" is not selling a drug, but it is speaking in the language of one.</p>
<p>Under India's food laws, products sold as foods or health supplements cannot claim to treat, cure or prevent disease. The Food Safety and Standards (Advertising and Claims) Regulations, 2018, restrict unsubstantiated claims and require that any health claim be supported by evidence. How a brand name interacts with those rules is precisely the sort of question that ends up in a regulatory letter.</p>
<h2>Celevida Was Built as Dr Reddy's Consumer-Health Bridge</h2>
<p>Celevida sits within Dr Reddy's nutrition portfolio &mdash; a line the Hyderabad-based drugmaker has developed as part of its push beyond prescription medicines into everyday consumer health.</p>
<p>The GLP+ variant arrived as weight management and metabolic health became mainstream conversation in India, driven by the visibility of GLP-1 drugs. The branding appears to position the product as nutritional support in that space, though the specifics of what was flagged have not been made public.</p>
<h2>Who Feels This First &mdash; Pharmacies, Dietitians and Dieters</h2>
<p>The immediate impact is on people who bought the product expecting a particular benefit. If the marketing language changes, their understanding of what the product does may need to change with it.</p>
<p>Pharmacists and nutritionists carry the second-order effect. They are the ones who field the question "is this the same as the injection?" &mdash; a question that a name like GLP+ invites and that no label can fully answer on its own.</p>
<h2>What Dr Reddy's Has Said &mdash; and What It Has Kept Quiet</h2>
<p>Company official Ramana, speaking at a press conference, confirmed the notice and the instruction to continue sales. That is the extent of the public account so far.</p>
<p>Dr Reddy's has not publicly listed the exact claims FSSAI objected to, the date of the notice, or whether the regulator raised concerns about the name itself or only about the advertising. Those gaps matter, because the fix differs sharply depending on which one is at issue.</p>
<h2>The Claim, Not the Product, Is the Real Battleground</h2>
<p>A food regulator is not usually in the business of judging whether a nutritional product works. It judges whether the label and the advertisement tell the truth about what the product does.</p>
<p>That distinction is why notices of this kind often end in revised packaging rather than in withdrawal. The product can remain identical while every sentence around it is rewritten.</p>
<h2>Confirmed Facts, and the Parts Still Unclear</h2>
<p>Confirmed: an FSSAI notice exists, Dr Reddy's is reviewing the brand name and advertising claims, and sales have been permitted to continue during the review.</p>
<p>Unclear: the specific claims flagged, the timeline FSSAI has set, whether the "GLP+" name itself is under challenge, and whether any penalty is contemplated. Any claim that the product has been found unsafe would be speculation &mdash; no such finding has been stated.</p>
<h2>Why Dr Reddy's Can Afford to Handle This Slowly</h2>
<p>Dr Reddy's is one of India's largest pharmaceutical companies, with a global generics business that gives it deep regulatory experience and the balance sheet to absorb a prolonged review.</p>
<p>Its real advantage in consumer health is distribution and brand trust &mdash; the same pharmacy counters and retail shelves that carry its medicines. Celevida is an attempt to convert that trust into a recurring, non-prescription purchase. That is a valuable franchise, and one worth defending carefully rather than quickly.</p>
<h2>The Risks Hiding Behind a Clever Name</h2>
<p>The obvious risk is reputational. A name that flatters a popular drug class can also invite the accusation that it is trading on another product's clinical reputation.</p>
<p>There is a commercial risk too. If the branding has to be softened, the product loses the instant recognition that made it distinctive on a crowded shelf. And there is a wider risk for the category: a single high-profile correction can make every nutrition brand in the metabolic-health space more cautious about its claims.</p>
<h2>India Is Tightening the Language of Nutrition Marketing</h2>
<p>This notice is not an isolated event. Regulators and advertising watchdogs have been steadily tightening scrutiny of health and nutrition claims &mdash; particularly where products appear to gesture at medical outcomes without the clinical evidence a drug would require.</p>
<p>The GLP-1 boom has accelerated that. As weight-loss medicines dominate headlines, the adjacent nutrition market has every incentive to borrow their vocabulary, and regulators have every reason to draw a line around it.</p>
<h2>If You Use Celevida GLP+, Here Is What to Do Now</h2>
<p>Nothing about the product's availability has changed, so there is no reason to stop using it on account of the notice alone. But it is worth reading the label for what the product actually is &mdash; a food or nutritional supplement &mdash; rather than what the name suggests.</p>
<p>Anyone using it alongside a prescribed GLP-1 medicine should treat it as a supplement and discuss it with their doctor. A brand name is not a prescription, and a nutrition product is not a substitute for medical treatment.</p>
<h2>What Happens Next</h2>
<p>The most likely outcomes are a revised set of marketing claims, a modified brand presentation, or both &mdash; with the product itself unchanged. A full withdrawal would be a far bigger step and has not been signalled.</p>
<p>Watch for three things: whether Dr Reddy's discloses what exactly it is changing, whether FSSAI publishes its own findings, and whether other nutrition brands follow with quieter edits of their own.</p>
<h2>Our Take</h2>
<p>This is a small regulatory notice with an outsized signal. It tests a habit that has become common across Indian consumer health &mdash; borrowing the vocabulary of a breakthrough drug class to sell something that is not a drug.</p>
<p>Dr Reddy's has handled the first move correctly by confirming the notice and keeping the product on shelves. The harder test is the second move: whether the company rewrites its claims clearly enough that a customer in a pharmacy queue understands what she is buying, and what she is not.</p>
<h2>Frequently Asked Questions</h2>
<h3>Is Celevida GLP+ banned or recalled?</h3>
<p>No. According to the company, FSSAI directed Dr Reddy's to continue selling the product while the flagged claims are reviewed. No recall has been announced.</p>
<h3>What exactly did FSSAI object to?</h3>
<p>The regulator flagged certain advertising claims, and the company is also reviewing the brand name. The specific claims have not been publicly detailed by Dr Reddy's or FSSAI.</p>
<h3>Is Celevida GLP+ the same as a GLP-1 weight-loss injection?</h3>
<p>No. It is a nutritional product sold under food regulations. GLP-1 medicines are prescription drugs and are regulated as pharmaceuticals, not as foods.</p>
<h3>Does a food regulator have the power to regulate advertising claims in India?</h3>
<p>Yes. FSSAI operates under the Food Safety and Standards Act, 2006, and its Advertising and Claims Regulations, 2018, govern how food and nutraceutical products may describe their benefits.</p>
<h3>Should people currently using the product stop?</h3>
<p>There is no stated safety concern. The review concerns claims and branding, not product safety. Users with medical conditions or those on prescribed GLP-1 therapy should consult their doctor about any supplement.</p>]]></content:encoded>
                <dc:creator><![CDATA[AI Global]]></dc:creator>
                <pubDate>Fri, 23 Oct 2026 18:15:54 +0000</pubDate>

                                    <media:content url="/storage/media/images/1792846025_images-22_article.webp" medium="image">
                        <media:title type="html"><![CDATA[Celevida GLP+ FSSAI Alert Keeps Sales Running]]></media:title>
                    </media:content>
                    <enclosure url="/storage/media/images/1792846025_images-22_article.webp" length="0" type="image/jpeg" />
                
                                    <category><![CDATA[Pharma]]></category>
                            </item>
            </channel>
</rss>